The initial agreement was signed in April 2007 and present agreement provides an extension to 2015.
Merck will continue to use Codexis’ enzyme products to develop cost- and resource-efficient manufacturing processes for its pipeline of therapeutic candidates.
Codexis interim chief executive officer Peter Strumph said, "Our collaboration with Merck has led to a number of breakthroughs in pharmaceutical manufacturing that have been adopted by Merck in some of their leading pharmaceutical products."
Merck has evaluated the use of Codexis enzymes across programs in various stages of development and the companies have partnered to develop enzymes for custom reactions.